Choose your Region

Are you sure you want to proceed?

You will be leaving the Cook Medical website that you were viewing and going to a Cook Medical website for another region or country. Not all products are approved in all regulatory jurisdictions. The product information on these websites is intended only for licensed physicians and healthcare professionals.

November 19th, 2019

Data show Zilver® PTX® leads to fewer complications and shorter hospital stays than traditional bypass surgery

Bloomington, Ind. – At this year’s VEITHsymposium®, Dr. Marc Bosiers presented data that show that patient treatment with the Zilver® PTX® stent has several benefits when compared to traditional bypass surgery. The data, which were gathered from a randomized controlled trial, showed that treatment with Zilver PTX results in fewer complications and shorter hospital stays for patients with peripheral artery disease (PAD).1

Zilver® PTX®, Cook Medical’s paclitaxel-coated stent

PAD affects more than 236 million people worldwide.2 Zilver PTX, Cook Medical’s paclitaxel-coated stent, is used to treat patients with PAD. To better understand the impact of Zilver PTX, Cook Medical funded a five-year physician-sponsored study called ZILVERPASS that compared the effects of treatment with Zilver PTX to traditional open prosthetic bypass surgery. The study was a randomized, multi-center trial that involved 220 patients in four countries.

The data presented at VEITHsymposium showed that the procedure with Zilver PTX takes about half the time as a bypass procedure. Patients who were treated with Zilver PTX had a hospital stay that was on average five days shorter. Thirty days after the procedure, patients who were treated with Zilver PTX for long and complex lesions were 60% less likely to have complications than patients who had bypass surgery. In addition, other clinical outcomes of Zilver PTX were comparable to those of bypass surgery according to the two-year data. This study is continuing to collect results through five years.

“Our mission with Zilver PTX—and with every product we make at Cook Medical—is to try to improve people’s lives. Cook Medical has released extensive data around Zilver PTX, and this device continues to show benefits across a wide spectrum of patients. We hope that by continuing the conversation around paclitaxel, physicians and patients can make more informed decisions,” said Mark Breedlove, vice president of Cook Medical’s Vascular division.

If you have questions about Zilver PTX, please contact us at, and a member of our team will respond within 24 hours. The VEITHsymposium presentation and additional Zilver PTX information are available at

Dr. Marc Bosiers is a paid consultant for Cook Medical.
VEITHsymposium is a registered trademark of Frank J. Veith.

About Cook Medical
Since 1963, Cook Medical has worked closely with physicians to develop technologies that eliminate the need for open surgery. Today, we are combining medical devices, biologic materials and cellular therapies to help the world’s healthcare systems deliver better outcomes more efficiently. We have always remained family owned so that we have the freedom to focus on what we care about: our patients, our employees and our communities. Find out more at, and for the latest news, follow us on Twitter, Facebook and LinkedIn.

1 Bosiers M. 2-year results of the ZILVERPASS RCT comparing Zilver PTX DES treatment to open prosthetic bypasses for long femop lesions. Paper presented at: 46th Annual VEITHsymposium; November 19, 2019; New York City, NY.

2 Song P, Rudan D, Zhu Y, et al. (2019). Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis. Lancet Glob Health. 2019;7(8):e1020-e1030.

Essential prescribing information (EPI) for Zilver® PTX®